Skip to Content

Generic Tuxarin ER Availability

Last updated on July 7, 2021.

Tuxarin ER is a brand name of chlorpheniramine/codeine, approved by the FDA in the following formulation(s):

TUXARIN ER (chlorpheniramine maleate; codeine phosphate - tablet, extended release;oral)

  • Manufacturer: MAINPOINTE
    Approval date: June 22, 2015
    Strength(s): 8MG;54.3MG

Has a generic version of Tuxarin ER been approved?

No. There is currently no therapeutically equivalent version of Tuxarin ER available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tuxarin ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
    Patent 9,066,942
    Issued: June 30, 2015
    Assignee(s): Spriaso LLC

    The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is about 4×10−4 moles to about 2.0×10−3 moles.

    Patent expiration dates:

    • January 3, 2032
      ✓ 
      Patent use: TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS
  • Oral dosage forms for oxygen containing active agents and oxyl-containing polymers
    Patent 9,107,921
    Issued: August 18, 2015
    Assignee(s): Spriaso LLC

    A pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The tablet is a matrix tablet and a single-dose administration of one or more tablets to a subject under fasted conditions provides a mean Cm˜ for each of the first active agent and the second active agent that is 70% to 135% of a respective mean Cm˜ provided by administering an immediate release oral dosage form to a subject under fasted conditions every 4 to 6 hours over a 12 hour time period, wherein cumulative dosage amounts administered over the 12 hour time period of each active agent is equivalent to the respective amount of each active agent in the pharmaceutical tablet.

    Patent expiration dates:

    • January 3, 2032
      ✓ 
      Drug product

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.